A few countries have sought to control pharmaceutical use and to raise revenues by introducing a copayment for cancer drugs. This may appear small, but given that cancer care costs are about 3-7% of total expenditure on health as described in Chapter 1, these costs actually comprise a significant part of spending in cancer care systems. Among the countries in which data were collected through the OECD questionnaire, Latvia and Spain spent less than 0.6% of total health expenditure on cancer drugs. Considering the limited number of countries for which data are available, the proportion of pharmaceutical spending is highest in Hungary, at 41.4% of total cancer care (not total health expenditure) in 2006.